| |
Day 1 |
| |
Agenda OPTIMUNISE Stakeholders Conference |
| |
The Proposed INDEPTH Strategic Plan, 2017-2021 |
| 00 |
NSE-stakeholder-optimunise-overview-final |
| 01 |
HDSS_Sites |
| 02 |
WHO SAGE recommendations on NSE |
| 03 |
Non-specific effects of vaccines NSE-stakeholder-non-specific effects of
vaccines |
| 04 |
Non-specific immunological effects of vaccines |
| 05 |
Randomised trials of BCG to low-birth-weight children in Guinea-Bissau, (Christine Benn) , The age of BCG vaccination and the decline in neonatal mortality: Evidence from Navrongo, Paul Welaga
|
| 06 |
Optimising the impact of BCG on neonatal mortality |
| 07 |
The role of measles vaccine (MV) in reaching MDG4 |
| 08 |
Effects and cost-effectiveness of Measles vaccination campaigns Evidence from Bandim Health Project
|
| 09 |
OPV campaigns – their role in reaching MDG4: Bandim and Navrongo |
| 10 |
Preliminary data from randomised trials |
| 11 |
Sex-differential effects of vaccines:Evidence from Bandim and Nouna |
| 12 |
Vitamin A Supplementation Contradicting single effect interventions |
| 13 |
The RTS,S vaccine trials: further evidence for NSE or other explanations? |
| 14 |
OPTIMUNISE Lessons learnt |
| 15 |
Group work summary |
